NCT05284942

Central China Rosai-Dorfman Disease Registry

A Trial to Evaluate the Long Term Prognosis in Rosai-Dorfman Disease

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Tongji Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a research study among patients with Rosai-Dorfman disease.

Detailed description

Rosai-Dorfman disease is a rare disorder characterized by overproduction (proliferation) and accumulation of a specific type of white blood cell (histiocyte) in the lymph nodes of the body (lymphadenopathy), most often those of the neck (cervical lymphadenopathy). In some cases, abnormal accumulation of histiocytes may occur in other areas of the body besides the lymph nodes (extranodal). These areas include the skin, central nervous system, kidney, and digestive tract. The symptoms and physical findings associated with Rosai-Dorfman disease vary depending upon the specific areas of the body that are affected. The disorder predominantly affects mainly adolescents or young adults. The exact cause of Rosa Dorfman disease is unknown. The purpose of this research study is to learn the prevalence , therapies and long term prognosis of Rosa Dorfman disease.

Conditions

• Rosai-Dorfman Disease
• Langerhans Cell Histiocytosis

Interventions

Type	Name	Description
DRUG	Mycophenolate mofetil combined with oral prednisone	Mycophenolate mofetil oral 500mg twice a day combined with standard of care of oral prednisone 5mg-15mg/day from baseline to week 108

Timeline

• Start date: 2011-10-01
• Primary completion: 2022-06-01
• Completion: 2022-06-01
• First posted: 2022-03-17
• Last updated: 2022-03-17

Locations

2 sites across 1 country: China